Up a level
Export as [feed] Atom [feed] RSS 1.0 [feed] RSS 2.0
Group by: Item Type | Date | No Grouping
Number of items: 3.

Journal Article

Hillmen, P., Soumerai, J., Zelenetz, A., Darif, M., Londhe, A., Xing, G., Huang, J., Lin, M., Byrd, J., Chanan-Khan, A., Furman, R., Hallek, M., Jones, J., Sharman, J., Ferrante, L., Reddy, V., Dreiling, L., Adewoye, H., Dubowy, R., Howes, A. and James, D. (2018). A Validated Risk Model for Overall Survival in Relapsed/Refractory Chronic Lymphocytic Leukaemia Applicable to Patients Treated with Novel Therapies and Standard of Care. Br. J. Haematol., 181. S. 75 - 76. HOBOKEN: WILEY. ISSN 1365-2141

Munir, T., O'Brien, S., Jones, J. A., Coutre, S. E., Mato, A. R., Hillmen, P., Tam, C., Osterborg, A., Siddiqi, T., Thirman, M. J., Furman, R. R., Ilhan, O., Keating, M., Call, T. G., Brown, J. R., Stevens-Brogan, M., Li, Y., Clow, F., James, D., Chu, A., Hallek, M. and Stilgenbauer, S. (2015). Results from the phase 2 RESONATE (TM)-17 Trial: Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic leukaemia with 17p deletion. Br. J. Haematol., 169. S. 71 - 72. HOBOKEN: WILEY. ISSN 1365-2141

Munir, T., O'Brien, S., Jones, J. A., Coutre, S. E., Mato, A. R., Hillmen, P., Tam, C., Osterborg, A., Siddiqi, T., Thirman, M. J., Furman, R. R., Ilhan, O., Keating, M., Call, T. G., Brown, J. R., Stevens-Brogan, M., Li, Y., Clow, F., James, D., Chu, A., Hallek, M. and Stilgenbauer, S. (2015). Results from the phase 2 RESONATE (TM)-17 Trial: Efficacy and safety of ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or small lymphocytic leukaemia with 17p deletion. Br. J. Haematol., 169. S. 71 - 72. HOBOKEN: WILEY. ISSN 1365-2141

This list was generated on Thu May 6 17:21:41 2021 CEST.